SpeeDx, a leading innovator in molecular diagnostic solutions, has announced the appointment of Jeremy Stackawitz as its Chief Executive Officer. With over 25 years of leadership experience in the life sciences and diagnostics sectors, Stackawitz will focus on accelerating SpeeDx’s commercialization efforts, as well as its partnerships and regulatory activities in key markets, including the United States.
“We are thrilled to welcome Jeremy as the new CEO of SpeeDx at a pivotal time for the company. We are also grateful to Colin Denver for his contributions and leadership during a period of significant milestones for the company,” said Jonathan O. Clark, Chairman of the SpeeDx Board. “Jeremy’s proven success in scaling businesses globally, along with his deep understanding of the diagnostics landscape, make him the ideal leader to guide our next phase of growth. With cutting-edge multiplexing technology, SpeeDx has the potential to transform testing, and we’re excited to see Jeremy lead the charge in expanding our global footprint.”
Stackawitz has joined SpeeDx from Senzo, where he served as CEO and was instrumental in securing financing, driving growth, and expanding the company’s product offerings. Previously, he held leadership positions at Quotient, where he significantly contributed to scaling the diagnostics organization. During his time there, he helped the company achieve multiple FDA product approvals, establish successful OEM partnerships, increase revenue and customer growth, and ultimately navigate its IPO. With a career spanning 25 years, Stackawitz has also worked at McKinsey & Company and Johnson & Johnson. He holds a bachelor’s degree from Dartmouth College and an MBA in Healthcare Management from The Wharton School.
“I am honored to join SpeeDx to help accelerate the company’s trajectory at such an exciting time of expansion,” said Stackawitz. “SpeeDx’s proprietary PlexPlus® PCR technology is revolutionizing the diagnostics industry by delivering faster, more cost-effective, and more comprehensive infectious disease testing. I look forward to building on the company’s strong foundation and working alongside the talented team to continue advancing our global impact and improving patient outcomes worldwide.”
For 15 years, SpeeDx has been dedicated to innovating the management of infectious diseases and enhancing patient outcomes. With a growing portfolio of products and partnerships with top diagnostic companies, SpeeDx is well-positioned to lead the next generation of molecular testing solutions.
